3 結果
Study design: This is a prospective not controlled, not randomized, unicentric study to establish predictive biomarkers for a safe and effective treatment withdrawal in patients with type 1 AIH.
Length of the study: Screening is expected to take a year. Treatment withdrawal will be done gradually
Autoimmune hepatitis (AIH) is an immune-mediated necroinflammatory disease of the liver characterized by elevation of IgG, presence of characteristic autoantibodies, and histological feature of interface hepatitis. Standard therapy consists of a combination of corticosteroids and azathioprine, which
TARGET POPULATION Inclusion criteria : Patients will be eligible if :
they fulfill the new American-European Consensus Group criteria for pSS and have :
- a recent (less than 10 years) and active disease as assessed by :
- values > 50 mm on 2 of 4 visual analogue scales (VAS) (0-100mm) that